Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

Paget's disease of bone
monostotic, quantitative bone scintigraphy in, 1506
tiludronate and etidronate in, 851
Pain
abdominal, in NSAID-induced gastroduodenal injury, 1225
assessment, in JRA, 1142
cerebral blood flow, in women with fibromyalgia, 926
in clenched fist syndrome, 57
guidelines for medical management of OA and, 1541
hydroxychloroquine and, 445
knee, directed examination of, and cartilage abnormalities, 917
low back, 1232, 1236
lower extremity, in lumbar spinal stenosis, 1236
prevalence and characteristics of fibromyalgia and, 19
in pseudoseptic inflammatory knee effusion in sickle cell disease, 284
in RA, 602, 727, 1107, 1177, 1568, 1807
Spanish outcome measures and, 1429
sulfasalazine in spondylarthropathy and, 618
thigh, 1236
vitamin B6 in rheumatoid cachexia and, 105
Palmar plaques, cutaneous LE exacerbation from ultraviolet emissions from a photocopier and, 1152
Pamidronate, intravenous, in quantitative bone scintigraphy in monostotic Paget's disease of bone, 1506
Pancreas, autoimmunity and, 301
Pancreatic islet disease, autoimmune, induction of, by microbial pathogens, 458
Pancytopenia, acute parvovirus B19-induced, after MTX in RA, 1023
Pannus, in RA, 151, 678
Papules
cutaneous LE exacerbation from ultraviolet emissions from a photocopier and, 1152
Gottron's, acanthosis nigricans and, 862
Paracortical region of popliteal lymph nodes, clodronate-containing liposomes in rat adjuvant arthritis and, 1777
Parainfluenza 1 and 3, enteroviral RNA, bacterial DNA and, in juvenile DM, 1513
Paramesangium, glomerulonephritis, C4 deficiency and, 1333
Parasites, autoimmune disease induction and, 458
Parental assessment, draft guidelines for drugs in JRA clinical trials and, 715
Parenteral MTX, effective shelf-life, cost and handling of, 575
Partial thromboplastin time, in bone marrow transplantation in antiphospholipid syndrome, 115
Parvovirus B19
acute pancytopenia induced by, after MTX in RA, 1023
infection, 638, 1174
Patellar cartilage
disruption of, directed knee examination, cartilage abnormalities and, 917
IL-1 in, in experimental arthritis in mice, 164
Patellofemoral compartment, directed knee examination, cartilage abnormalities and, 917
Patellofemoral joints, knee OA in, in athletes, 539
Pathogenesis
of AIDS, 1701
of autoimmune diseases, 458, 1738
evaluative laboratory testing and, 1555
Fc receptor IIa polymorphism in renal disease in SLE and, 1832
IgG receptors in autoimmune disease and, 306
IL-1α in JRA and, 221
in infection and onset of giant cell arteritis, 374
in Lyme borreliosis, 565
in NSAID-induced gastrointestinal mucosal damage, 5
of OA, 420, 907
of RA, 384, 577, 678, 1328, 1701
in Raynaud's phenomenon and scleroderma, 1
of spondylarthropathies, 1547
of swelling, nitric oxide synthase in articular chondrocytes in, 1529
TAP alleles, Reiter's syndrome and, 684
TGFβ1 in hyaluronan synthesis in synovial lining cells and, 669
Yersinia enterocolitica adhesin YadA, on collagen and, 1282
Pathogenetics
antineutrophil cytoplasmic antibodies in mice and, 1375
cognitive deficit in rheumatic diseases and, 1361
of IL-1 receptor antagonist in RA, 642
soluble Fas/APO-1/CD95 and, in SLE and JRA, 1735
Pathogens
extracellular and intracellular, in pathogenesis of spondylarthropathies, 1547
microbial, autoimmune disease induction by, 458
Pathology
in IL-1 in experimental arthritis in mice, 164
lipoprotein oxidation, SSc and, 1060
micro-, spin-spin relaxation of brain in SLE and, 810
MTX, prednisone and, in Wegener's granulomatosis, 608
in RA, 1025, 1618
Pathophysiology
of IL-1 receptor antagonist in SLE, 1055
in NSAID-induced gastrointestinal mucosal damage, 5
in RA, IL-1, TNFα and, 151
in Raynaud's phenomenon and scleroderma, 1
tenidap in experimental canine OA and, 1290
tuberculous and foreign-body granulomatous reactions involving a total knee prothesis and, 1325
Patient assessment
Arthritis Knowledge Questionnaire and, 590
global, 601, 618, 727, 1107, 1568, 1826
in RA, 601, 727, 1107, 1568
in SLE, 1826
in sulfasalazine-treated spondylarthropathy, 618
Patient education
in guidelines for medical management of OA, 1535
about MTX, 874
Patient subsets, in SLE, 1475
Pauciarticular JRA
cytokines in, 211
HLA-B39 in, 1672
IL-1α polymorphism in, 221
juvenile AS and, 835
Paulus criteria, human monoclonal antibody CAMPATH-1H in refractory RA and, 1187
Pediatric rheumatology
ACR Slide Collection and, 1733
enteroviral RNA and bacterial DNA in juvenile DM, 1513
FDA draft Guidelines for Antiinflammatory and Antirheumatic Drugs in Children, 715
JRA, 211, 221, 446, 1142
juvenile AS, 835
Lyme arthritis in Europe, 361
MTX in, 575
NSAID-induced gastroduodenal injury, 1225
Pedicle, in spinal involvement in gout, 139
p84, cytokines, early response genes and, 877
Pelvis, radiographic hip OA, bone mineral density and, 907
Penicillamine
nitric oxide and lipoxin A4 in polymorphonuclear vascular cytotoxicity and, 768
in RA, 242, 318
Peptides
antigenic, TAP alleles, Reiter's syndrome and, 684
Arg-Gly-Asp (RGD), IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
bacterial, 1547
calcitonin gene-related, substance P and, in rat adjuvant arthritis, 699
HLA-B39 and, in AS and pauciarticular JRA , 1672
in pathogenesis of spondylarthropathies, 1547
p4 pocket, binding of, to DRB1*0401, 1744
synthetic, 1282, 1660
T cell receptors in RA and, 577
Perforin mRNA, granzyme A and, in RA synovium, 477
Perfusion-phase scintigraphic abnormalities, bone turnover and, in OA, 78
Periarteriolar lymphatic sheaths, of spleen, clodronate-containing liposomes in rat adjuvant arthritis and, 1777
Perineurial vasculitis, peripheral neuropathy with necrotizing vasculitis in RA and, 1618
Perinuclear antineutrophil cytoplasmic antibodies, in SLE, 633
Periodic acid-Schiff stain, to study glomerulonephritis, and C4 deficiency, 1333
Periosteal new bone formation, in adjuvant arthritis in rats, 129
Peripheral blood
Klebsiella pneumoniae-reactive T cells in AS and, 1277
lymphocytes, 254, 1187
monocytes, 946
mononuclear cells, 105, 485, 506, 577, 601, 877, 1771
neutrophils, in Behcet's disease, 426
parvovirus B19 infection, chronic fatigue syndrome and, 638
in RA, 151, 254, 577, 649, 1242, 1771
soluble adhesion molecules in disease activity in SSc and, 184
synovial T cells, IL-10 and, 946
Peripheral CD4 T cells, T cell receptors in RA and, 1242
Peripheral eosinophilia, cognitive deficit in rheumatic diseases and, 1361
Peripheral joints, T cell receptors in RA and, 577
Peripheral lymphocytes, CAMPATH-1H in refractory RA and, 1589
Peripheral lymphocytopenia, oral 2-chlorodeoxyadenosine in psoriatic arthritis and, 1604
Peripheral lymphoid organs, autoimmune disease induction by microbial pathogens and, 458
Peripheral lymphoid tissue, IL-1 receptor antagonist in SLE and, 1055
Peripheral lymphopenia, T cell receptors in RA and, 1242
Peripheral nervous system, in Raynaud's phenomenon and scleroderma, 1
Peripheral neuropathy with necrotizing vasculitis in RA, 1618
Peripheral T cells
CD4, depletion of, after chimeric monoclonal anti-CD4 antibody and MTX in RA, 1581
Klebsiella pneumoniae-reactive T cells in AS and, 1277
Perivascular infiltration, cathepsin, collagenase and, in RA, 976
Perivascular mononuclear cell infiltrates, antineutrophil cytoplasmic antibodies in mice and, 1375
Peroxynitrite, nitric oxide and lipoxin A4 in polymorphonuclear vascular cytotoxicity and, 768
Persistent bacterial antigen, pathogenesis of spondylarthropathies and, 1547
Personality, cognitive deficit in rheumatic diseases and, 1361
p4 peptide pocket, binding of, to DRB1*0401, 1644
p48 polypeptide, cytokines, early response genes and, 877
p50 nuclear factor κB in rheumatoid synovium, 1762
p55 soluble TNF receptor, in JRA, 211
p65 nuclear factor κB in rheumatoid synovium, 1762
Phagocytes, clodronate-containing liposomes in rat adjuvant arthritis and, 1777
Phagocytosis, pseudoseptic inflammatory knee effusion caused by, in sickle cell disease, 284
Phagosomes, Chlamydia trachomatis in synovial membranes and, 1410
Pharmacies and pharmacology
cost of drugs in RA and, 318
IgG receptors in autoimmune disease and, 306
immunosuppressive drugs during pregnancy and, 1722
Pharmacokinetics, FDA draft guidelines for drugs in JRA clinical trials and, 715
Phenotypes
chondrocyte, proteoglycan synthesis and, in canine OA, 525
HLA-B51, in peripheral blood neutrophils in Behcet's disease, 426
mannose-binding protein gene polymorphism in SLE and, 110
in RA, 254, 1014, 1046, 1242
scleroderma in Tsk2 mouse and, 1791
TAP alleles, Reiter's syndrome and, 684
Phlogistic effects of MSU, bone marrow fat in inflammatory response to sickled erythrocytes and, 1349
Phorbol ester, nitric oxide and lipoxin A4 in polymorphonuclear vascular cytotoxicity and, 768
Phorbol myristate acetate
nitric oxide and lipoxin A4 in polymorphonuclear vascular cytotoxicity and, 768
synovial T cells, IL-10 and, 946
Phosphatase, alkaline, 292, 477, 499, 851, 902, 1194, 1506
Phosphate
MRI/MRS in DM and, 68
pyridoxal-5`, vitamin B6 in rheumatoid cachexia and, 105
Phospholipids
in bone marrow transplantation in antiphospholipid syndrome, 115
human monoclonal antiphospholipid antibody and, 1068
NSAID, gastrointestinal tract and, 5
Phosphorylation
antiinflammatory mechanism of adenosine regulators and, 1040
tyrosine, IgG receptors in autoimmune disease and, 306
Photoexacerbation, of cutaneous LE, from ultraviolet photocopier emissions, 1152
Physical abuse, childhood sexual abuse, fibromyalgia and, 161, 229, 235
Physical examination, compartment-directed, of knee, cartilage abnormalities and, 917
Physical loading, knee OA in athletes and, 539
Physical therapists
Arthritis Knowledge Questionnaire and, 590
guidelines for medical management of OA and, 1541
Physician assessment
draft guidelines for drugs in JRA clinical trials and, 715
evaluative laboratory testing and, 1555
global, 601, 618, 727, 1107, 1568, 1826
in RA, 727, 1107, 1568
self-administered RADAI in epidemiology and, 795
in SLE, 1826
in sulfasalazine-treated spondylarthropathy, 618
Physicians and surgeons
access to medical care for musculoskeletal conditions and, 1128
American Board of Internal Medicine recertification program in rheumatology and, 1169
in cost and impact of musculoskeletal conditions, 1351
primary care, continuing medical education in rheumatic diseases for, 533
Physiology
cardiovascular fitness in end-stage OA and, 799
MRI, PET and, in RA, 819
nitric oxide synthase in articular chondrocytes in pathogenesis of swelling and, 1529
PiMZ α1-antitrypsin phenotype, end-stage liver disease after MTX in α1-antitrypsin deficiency and, 1014
Piroxicam
gastrointestinal tract and, 5
in RA, 29
Placebo, NSAID, gastrointestinal tract and, 5
Placenta, antibodies to synovial antigens in early RA and, 1418
Placoid pigment epitheliopathy, acute posterior multifocal, in systemic JRA, 446
Plaque, palmar, cutaneous LE exacerbation from ultraviolet emissions from a photocopier and, 1152
Plasma
folate, vitamin B6 in rheumatoid cachexia and, 105
IL-6, tenidap in RA and, 1447
lipoprotein oxidation, SSc and, 1060
Plasma exchange, corticosteroids, pulse cyclophosphamide and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
Plasma IL-1β, tenidap, piroxicam and, in RA, 29
Plasmid
adhesin YadA, Yersinia enterocolitica, on collagen, 1282
Chlamydia DNA, in reactive arthritis, 1005
Platelet-derived growth factor
chondrocytes in aging and development and, 960
early response genes and, 877
Platelets
activation of, in Raynaud's phenomenon and scleroderma, 1
cytokines in JRA and, 211
in Felty's syndrome and large granular lymphocyte syndrome, 1352
Lyme borreliosis and, 565
Pleiomorphic effects, of IgG receptors in autoimmune disease, 306
Pneumonia
cytomegalovirus, diagnosis of, 1528
interstitial, cytomegalovirus and, after MTX in RA, 291
Pneumonitis, cytomegalovirus and, in RA after MTX, 1861
p91, cytokines, early response genes and, 877
Political factors and lobbying, rheumatology and, 451
Polyacrylamide gels, to study proteoglycans in articular cartilage in OA and RA, 660
Polyarteritis nodosa (PAN)
corticosteroids, pulse cyclophosphamide and plasma exchange in, 1638
cutaneous, associated with Crohn's disease and atrial myxoma, 1161
Polyarthritis
symmetric, AIDS in active RA, 1701
Ureaplasma urealyticum destructive septic, common variable immunodeficiency in, 1524
Polychondritis, relapsing, cartilage matrix protein in, 294
Polyclonal antibodies, anti-IL-1, IL-1 and, in experimental arthritis in mice, 164
Polyclonal B cells, activation of, in Lyme borreliosis, 565
Polyclonal T cells, cytolytic activity of, in SLE, 506
Polyethylene glycol-precipitated immune complexes, in RA, carbohydrates in, 744
Polyglot and polymorphism, 1715
Polymerase chain reaction
autoimmune disease induction by microbial pathogens and, 458
Chlamydia DNA in reactive arthritis and, 1005
DNA binding of IgM[gl] anti-DNA antibody and, 389
mannose-binding protein gene polymorphism in SLE and, 110
in RA, 96, 577, 1526, 1754
reverse transcriptase, 413, 1077, 1400, 1513
to study Chlamydia DNA in reactive arthritis, 1005
to study COL2A1 gene mutations in chrondrodysplasia and familial OA, 999
to study HTLV-1 in PM, 690
to study Lyme borreliosis, 565
to study Lyme disease in patient with symptoms of DM, 1157
to study parvovirus B19 infection and chronic fatigue syndrome, 638
to study pediatric Lyme arthritis, 361
Polymerase chain reaction-restriction fragment length polymorphism, to study HLA-DR8 and acute anterior uveitis in AS, 547
Polymerase chain reaction-sequence specific oligohybridization, to study HLA-B39 in AS and pauciarticular JRA, 1672
Polymorphisms
anti-U1 RNA antibodies in connective tissue disease and, 1837
IgG receptors in autoimmune disease and, 306
IL-1α, in JRA, 221
polyglot and, 1715
restriction fragment length, 91, 547
in SLE, 110, 1832
TAP alleles, Reiter's syndrome and, 684
Polymorphonuclear neutrophil vascular cytotoxicity, nitric oxide
and lipoxin A4 in, 768
Polymyalgia rheumatica, epidemiology of, in Olmsted County, MN, 369
Polymyositis (PM)
adult respiratory distress syndrome and anti-Jo-1 antibody in, 1519
functional disability in, 1218
HTLV-1 in, 690
immunosuppressive drugs during pregnancy and, 1722
pulmonary fibrosis, hepatitis C and, 437
Polypeptides
cytokines, early response genes and, 877
HLA type in MCTD and, 259
U1 snRNP antibodies, anti-U1 RNA antibodies in connective tissue disease and, 1837
Polyunsaturated fatty acids, NSAID, gastrointestinal tract and, 5
p113, cytokines, early response genes and, 877
Popliteal lymph nodes, paracortical region of, clodronate-containing liposomes in rat adjuvant arthritis and, 1777
Porphyria cutanea tarda, after hydroxychloroquine in SLE, 440
Positron emission tomography (PET), MRI and, in RA, 819
Posterior multifocal placoid pigment epitheliopathy, acute, in systemic JRA, 446
Postmenopausal women, steroids, hormone replacement and bone metabolism in RA in, 902
Practice guidelines, 1533
Prednisone
in acute posterior multifocal placoid pigment epitheliopathy in JRA, 446
dehydroepiandrosterone in SLE and, 1826
immunosuppressive drugs during pregnancy and, 1722
in NSAID-induced gastroduodenal injury in children, 1225
pulse cyclophosphamide, plasma exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
in RA, 29, 334, 819
in Wegener's granulomatosis, 608
Pregnancy
ectopic, 1722
immunosuppressive drugs during, 1722
lupus, fatal pulmonary complication of, 710
Preliminary definition of improvement in RA (ACR), 727
Preneoplastic disorder, mixed cryoglobulinemia as, 1859
Prescription drugs, in Chinese herbal medications, 614
Prevalence studies
antineutrophil cytoplasmic antibodies in SLE, 633
AS in twins in Finland, 381
epidemiology of polymyalgia rheumatic in Olmstead County, MN and, 369
fibromyalgia in the general population, 19
SLE in Birmingham, England, 551
Preventive medicine, risk factors for septic arthritis in joint disease and, 1819
Primary antiphospholipid syndrome
bone marrow cell transplantation and, 115
HLA-DR5 (DRB1*1201) in, in Mexican patients, 1340
human monoclonal antiphospholipid antibody in, 1068
Primary bilary cirrhosis, autoantibodies to pyruvate dehydrogenase in SSc and, 985
Primary care physicians
continuing medical education in rheumatic diseases for, 533
diagnosis of arthritis by, 448
prevalence and incidence of SLE in Birmingham, England and, 551
RA and, 315
rheumatology and, 451
Primary Raynaud's phenomenon, lipoprotein oxidation, SSc and, 1060
Primary Sjogren's syndrome, antibodies to synovial antigens in early RA and, 1418
Primate studies, antigen-based heteropolymers, 190
Primed neutrophils, circulating, antineutrophil cytoplasmic antibody-negative pulmonary capillaritis and, 1855
Private practice rheumatology, future of, 451
Problems Elicitation Technique, outcome measures in RA clinical trials and, 1568
Procollagen
α1(I), mRNA, scleroderma in Tsk2 mouse and, 1791
type II, COL2A1 gene mutations in chrondrodysplasia and familial OA and, 999
Prodrugs, NSAID, gastrointestinal tract and, 5
Progressive joint destruction, in HIV infection in RA, 1328
Progressive knee OA, in the elderly, 1500
Proinflammation, IgG receptors in autoimmune disease and, 306
Proinflammatory states, IL-1 receptor antagonist in RA and, 642
Prokaryotes, in pathogenesis of spondylarthropathies, 1547
Prolactin, cytokines, early response genes and, 877
Proliferating cell nuclear antigen, synovial membrane in RA and, 1346
Proliferation assays, to study Klebsiella pneumoniae-reactive T cells in AS, 1277
Proliferative response, lymph node, in bone marrow transplantation in antiphospholipid syndrome, 115
Prophylaxis, Lyme borreliosis and, 565
Propoxyphene, guidelines for medical management of OA and, 1535
Prostaglandins, NSAID, gastrointestinal tract and, 5
Prosthetic joints
hip, infected, loosening of revision total hip replacement in RA and, 1315
risk factors for septic arthritis in joint disease and, 1819
Protease
inhibitors, 1694
neutrophil, rheumatoid synovial fibroblast adhesion to human articular cartilage and, 1694
serine granzyme A, perforin mRNA and, in RA synovium, 477
Protein
A, 396, 1418
A2, 777
acute-phase, 29, 642, 1447
aggrecan core, stromelysin degradation of cartilage and, 1678
AP-1, nuclear factor κB in rheumatoid synovium and, 1762
Arg-Gly-Asp (RGD), IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
autoimmune disease induction by microbial pathogens and, 458
autoimmune response to the spliceosome and, 777
B1, B2, 777
B/B`, 396
basic myelin, 458
bacterial, 1283
β-galactosidase fusion, autoepitopes of 52-kd SS-A/Ro molecule and, 990
bone Gla, bone turnover, bone mass and, after estrogen, 292
C, 396
cartilage matrix, in relapsing polychondritis, 294
c-Fos, 678
clearance, synovitis and, 1085
core, 660
C-reactive, in RA, 601, 969, 1204, 1447
cytokines, early response genes and, 877
deficiency, 1713
eosinophil major basic, 939
eukaryotic, IgG receptors in autoimmune disease and, 306
45-kd, 1418
G-purified IgG, 1485
guanylate binding, 877
HTLV gp46 envelope, 690
HTLV-1 in PM and, 690
human, 1655
IL-1 in experimental arthritis in mice and, 164
IL-2 diphtheria fusion (DAB486IL-2), 1177
isoforms, IgG receptors in autoimmune disease and, 306
keyhole limpet hemocyanin, type II collagen in antigen-induced arthritis and, 1092
ligand-binding, 877
lipid-binding, 1655
loss of, NSAID, gastrointestinal tract and, 5
Lyme borreliosis and, 565
MA1, 1655
major outer membrane, Chlamydia trachomatis in synovial membranes and, 1410
mannose-binding, deficiency of, 1713
MHC class II genes, anti-U1 snRNP antibody and, 396
Mi-2 autoantigen in DM and, 123, 1389
native, 1660
natural nuclear, 1389
neuronal, Lyme borreliosis and, 565
in OA, 420, 660
in pathogenesis of spondylarthropathies, 1547
in RA, 29, 151, 477, 492, 601, 660, 678, 744, 1177, 1418
recombinant, 1389, 1660
retroviral element-encoded nuclear, 1660
ribosomal, 1547
70K, 396
70-kd, 1660
60-kd heat-shock, 565, 1547
in SLE, 110, 1485, 1655, 1660, 1713
35S-methionine-labeled HEp-2 cell, 1389
stromelysin-cleaved rabbit aggrecan and, 1400
218-kd nuclear protein, 1389
unknown, autoantibodies in SSc in twins and, 1845
urinary, 29
viral-coated, autoimmunity and, 301
Yersinia enterocolitica adhesin YadA, on collagen and, 1282
Proteinase
Arg-Gly-Asp (RGD), IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
3, antineutrophil cytoplasmic antibodies in SLE and, 633
Proteinuria, in RA, 242, 1447, 1851
Proteoglycans
cartilage, 164, 660, 953, 1400
degradation of, IL-1 in experimental arthritis in mice and, 164
glycosaminoglycan epitopes in knee joint fluid after trauma and, 953
loss of, 1678
matrix, 173
metabolism of, 655
Mi-2 autoantigen in DM and, 1389
Proteoglycans (cont'd)
monoclonal antibodies in detection of biochemical markers of arthritis and, 655
in OA, 660
in RA, 660
stromelysin and, 173, 1400
synthesis of, 164, 525, 655
Proteolysis, Lyme borreliosis and, 565
Proximal interphalangeal joints, joint space measurement of, with computerized image analysis, 891
Proximal muscle weakness, Lyme disease in elderly forester with symptoms of DM and, 1157
P-selectin
in Lyme borreliosis, 565
soluble, disease activity in SSc and, 184
Pseudoseptic inflammatory knee effusion, in sickle cell disease, 284
Psoriatic arthritis
HLA and disease progression in, 845
immunosuppressive drugs during pregnancy and, 1722
pathogenesis of spondylarthropathies and, 1547
refractory, oral 2-chlorodeoxyadenosine in, 1604
sulfasalazine in, 573, 618
Psoriatic Task Force, ACR recommendations for liver biopsy in RA, after MTX, 1115
Psychiatric symptoms, cognitive deficit in rheumatic diseases and, 1361
Psychiatric syndromes, hand involvement, 57
Psychiatry and psychiatrists
childhood sexual abuse, fibromyalgia and, 161, 229, 235
cognitive deficit in rheumatic diseases and, 1361
Psychological factors
in clenched fist syndrome, 57
in cost and impact of musculoskeletal conditions, 1351
in prevalence and characteristics of fibromyalgia, 19
in walking velocity in elderly, 343
Psychology and psychologists, Arthritis Knowledge Questionnaire and, 590
Psychometric testing
Arthritis Knowledge Questionnaire and, 590
Spanish outcome measures and, 1429
Psychosis
cognitive deficit in rheumatic diseases and, 1361
spin-spin relaxation of brain in SLE and, 810
Pulmonary arterioles and artery, in fatal pulmonary vasculitis in lupus pregnancy, 710
Pulmonary capillaritis, antineutrophil cytoplasmic antibody-negative, circulating primed neutrophils and, 1855
Pulmonary fibrosis
hepatitis C, PM and, 437
in SSc, 939, 1024
Pulmonary function, eosinophil major basic protein in SSc and, 939
Pulmonary hypertension, in fatal pulmonary vasculitis in lupus pregnancy, 710
Pulmonary involvement
draft guidelines for drugs in JRA clinical trials and, 715
fatal pulmonary complication of lupus pregnancy, 710
in SSc, cyclophosphamide in, 147
Pulmonary vasculitis, fatal, in lupus pregnancy, 710
Pulse-chase experiments, to study complement in RA, 492
Pulse cyclophosphamide, corticosteroids, plasma exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
Purine analogs, immunosuppressive drugs during pregnancy and, 1722
Purine enzymes, azathioprine toxicity and, in RA, 142
Putative infection, enteroviral RNA, bacterial DNA and, in juvenile DM, 1513
Pyridinolone, urinary, bone turnover, bone mass and, after estrogen, 292
Pyridoxal-5`-phosphate, vitamin B6 in rheumatoid cachexia and, 105
Pyrophosphate
calcium, synovitis in rabbit OA and, 201
CPPD crystals, pseudoseptic inflammatory knee effusion in sickle cell disease and, 284
Pyruvate dehydrogenase, autoantibodies to, in SSc, 985